Modern SUS has become more adopted by the industry from the mid-2000s with almost all bioprocessing equipment available as a SUS. Multiple SUS bioreactor-based systems in parallel, or even a single system, can compete with stainless steel and produce enough to supply commercial markets at a certain scale. The advances in this technology are cost-effective to support pre-commercial manufacturing for preclinical and clinical supplies.

Join us to learn the ultimate benefits of SUS and the regulatory set in Latinamerica towards the use of this technology that benefits the dynamic of the bioprocesses in the industry.

Who will
you meet?

 

More than:

Participants

Companies

HCPs

Patients

Academy

Investors

Institutions

Associations

Service Providers

Government Agencies

Industry Executives from Latam

From these areas:

  • Biosimilars
  • Biobetters
  • Biotechnology
  • Biotherapeutics
  • Analytical science
  • Regulatory compliance
  • Quality Control
  • Clinical immunology
  • Scientific Affairs
  • Pharmacovigilance
  • Research
  • Regulatory
  • Business Development
  • Marketing

Speaker Board

Program at a Glance

Single-use Process Equipment: Understanding Regulatory Expectations for Validation Strategy.
Regulatory Parity in Single-use Component Validation

(COFEPRIS, INVIMA, ANVISA, PDA)

Best Practices in Process Safety: Practical Aspects of Sterilizing Grade Filter Validation in the Light of GMP

(Filtration and Fluid Management Technologies)

Process Validation

Challenges: Building Production Plants with Different Requirements (SS vs SUS)

(COFEPRIS, INVIMA, ANVISA)

Success Story
Case Study
Round Table: Key Factors for Successful Validation
Full programme in the PDF Agenda

Download Agenda

How to attend?

Keep me updated